CME/CE Accredited Session
Sponsored by Industry
Click For Session Details
Session Times Listed in ET
Peter Libby, MD
With the COVID-19 pandemic moving through the country, it is important for clinicians to have the most up-to-date information. Join this session with Dr. Peter Libby to learn about the cardiovascular complications of COVID-19 and how you can help patients facing these issues.
Cardiovascular Specialist, Brigham and Women's Hospital, Mallinckrodt Professor of Medicine, Harvard Medical School, Boston, MA
Christopher Cannon, MD | Tina K. Thethi, MD, MPH
In recent years there has a been paradigm shift in how to individualize use of antihyperglycemic agents in people with type 2 diabetes, with cardiac history and risk factors significantly affecting the guideline-recommended agents. In addition metformin, SGLT2 inhibitors and GLP-1 receptor agonists have become an integral part of treatment of patients with diabetes and comorbid cardiac and renal disease. Join expert faculty in this data driven session as they review the and discuss strategies to improve use of these agents in management of type 2 diabetes.
Cardiovascular Division, Brigham and Women's Hospital, Professor of Medicine, Harvard Medical School, Boston, MA
Associate Investigator and Endocrinologist, AdventHealth, Translational Research Institute, Orlando, FL
Supported by Novo Nordisk Inc.
Clinical Insights in CAD and/or PAD: Reducing the Risk of Major Cardiovascular Events
Vinay Satwah, MD
Patients with coronary artery disease (CAD) and/or peripheral artery disease (PAD) are at risk for major cardiovascular events, including cardiovascular death, myocardial infarction, and stroke. This lecture will discuss an approach to reducing the risk of these events.
Sponsored by Janssen Pharmaceuticals, Inc.
Confronting Cardio-Oncology: An Emerging Epidemic
Javid Moslehi, MD
The development of cardio-oncology as a clinical field has been driven by improved therapeutics resulting in a dramatic increase in the number of cancer survivors (~17,000,000 in the United States alone), many of whom suffer cardiovascular complications related to their cancer treatments. Both "traditional" and "targeted" therapies can affect the cardiovascular system resulting in hypertension, heart failure, myocarditis, arrhythmias, vascular disease, and thrombosis. While recurrence of cancer is the eventual cause of death in many "cancer survivors," cardiovascular disease is responsible for substantial morbidity and mortality in this population. Thus, effective means of mitigating cardiovascular complications of cancer therapies would have substantial impact on health. Here we will review novel issues in cardio-oncology and will give a broad overview of this emerging field.
Associate Professor of Medicine, Director, Cardio-Oncology Program, Co-Director, Vanderbilt Program for Optimizing Immuno-oNcology Therapy (V-POINT), Vanderbilt School of Medicine, Nashville, TN
Living in a World with COVID-19: From Reaction to Action
Alexander Liakos | Anil Gupta | Ravi Gupta | Beatriz Grinsztejn
The podcast focuses on the scientific understanding of SARS-CoV-2, in addition to the clinical management of patients with COVID-19 or long term sequalae. We bring together healthcare professionals from UK, Canada and Latin America to discuss COVID-19, variants, and how they are managing patients with COVID-19.
GSK Global Medical Director (UK)
Faculty of Medicine, University of Toronto (Canada)
Cambridge Institute of Therapeutic Immunology and Infectious Disease (UK)
Evandro Chagas National Institute of Infectious Diseases, Fiocruz, Rio de Janeiro (Brazil)
Sponsored by GlaxoSmithKline